Patients Needed for New Mesothelioma Clinical Trial

A new investigational drug for mesothelioma can now begin human trials after it was granted fast-track designation by the U.S. Food and Drug Administration last week. The novel treatment, SnyKIR-110, is a T-cell therapy designed to treat patients with mesothelioma, cholangiocarcinoma (bile duct cancer) and ovarian cancer.  “We are thrilled to receive fast-track designation from the FDA,” said Dr. Bryan Kim, co-founder and CEO of Verismo Therapeutics. “This designation is an important milestone in our efforts to bring this potentially life-saving drug to patients who are in need of new treatment options.” Fast-track designation is a process that helps develop and review new drugs that treat serious conditions and fill an unmet medical need. The main purpose is to get new drugs to the patient sooner, according to the FDA. Recruitment for Human Trials Underway Verismo Therapeutics is now recruiting patients to be part of the trial at the University of Pennsylvania in Philadelphia. The phase 1 clinical trial will be conducted with patients who have specific cancerous tumors. It will evaluate the drug’s safety and effectiveness and determine the best dosage. Verismo plans to enroll as many as 42 adult patients with confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma. Patients must have completed at least one prior line of systemic therapy ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news